Hoddevik G H
Statens senter for epilepsi, Sandvika.
Tidsskr Nor Laegeforen. 2000 Mar 30;120(9):1042-5.
Since 1950 the carbonic anhydrase inhibitor acetazolamide has been used as an antiepileptic drug. Because of its tolerance developing properties, acetazolamide has probably been bypassed by the new antiepileptic drugs on the market. However, when taken for 14 day periods with one week's stop in between, acetazolamide is still of value in the treatment of epilepsy.
The paper discusses acetazolamide and its present use in antiepileptic treatment in the light of existing internal control and quality assurance requirements in the medical services.
Irrespective og type of seizure, about 90% of patients have an initial reliable effect from acetazolamide, though it is uncertain how long the effect will last after repeated periods of use. As an additional drug, acetazolamide may be particularly well suited for women with menses-related seizures.
Acetazolamide may be the drug of choice when drug interaction is a problem, when rapid onset of effect is wanted, or when an additional drug is needed for a short period of time only.
自1950年以来，碳酸酐酶抑制剂乙酰唑胺一直被用作抗癫痫药物。由于其耐受性发展特性，乙酰唑胺可能已被市场上的新型抗癫痫药物所取代。然而，当每隔一周服用14天，中间停药一周时，乙酰唑胺在癫痫治疗中仍有价值。
本文根据医疗服务中现有的内部控制和质量保证要求，讨论了乙酰唑胺及其在抗癫痫治疗中的当前应用。
无论癫痫发作类型如何，约90%的患者最初使用乙酰唑胺有可靠疗效，尽管反复使用后疗效能持续多久尚不确定。作为辅助药物，乙酰唑胺可能特别适合与月经相关癫痫发作的女性。
当存在药物相互作用问题、需要快速起效或仅在短时间内需要辅助药物时，乙酰唑胺可能是首选药物。
